Pioneering ALS Prevention: Jeff Vierstra's Experimental Treatment Offers Hope
Jeff Vierstra, 41, with a family history of Amyotrophic Lateral Sclerosis (ALS) linked to a FUS gene mutation, has been undergoing an experimental treatment at Columbia University's Eleanor and Lou Gehrig ALS Center for three years. The treatment involves spinal infusions designed to target and disable the mutated gene. Following one year of treatment, abnormalities detected in Vierstra's muscle testing normalized, and he has not developed ALS, outliving many affected family members. This intervention represents an early effort to prevent the neurodegenerative disease in a high-risk individual.
Following one year of treatment, abnormalities detected in Vierstra's muscle testing normalized, and he has not developed ALS, outliving many affected family members.
A Family's Struggle and Genetic Risk
Jeff Vierstra is a scientist whose mother, two sisters (Erin and Leigh), and his mother's siblings died from complications related to Amyotrophic Lateral Sclerosis (ALS), often in their late thirties and early forties. Vierstra and his sisters tested positive for a mutation of the "FUS" gene. This mutation is associated with a high likelihood of developing ALS and plays a critical role in normal cell function, particularly in nerve cells.
ALS, also known as Lou Gehrig's disease, causes the progressive degeneration of motor neurons, leading to the loss of muscle control, including the ability to walk, talk, and breathe. There is currently no cure for the condition. Approximately 10-15% of ALS cases are genetic, with about two-thirds being familial. An estimated 35,000 people in the United States live with ALS.
The Experimental FUS Gene Therapy
Vierstra's sisters previously participated in a clinical trial at the Eleanor and Lou Gehrig ALS Center at Columbia University for an experimental treatment targeting the mutated FUS gene. Dr. Neil Shneider, a Columbia University neurologist leading the trial, examined Vierstra and identified abnormalities on his electromyography (EMG) scans, which can indicate an early sign of potential disease onset.
Dr. Shneider subsequently offered Vierstra the same experimental treatment administered to his sisters. For the past three years, Vierstra has received spinal infusions every few months. These infusions are designed to target and disable the mutated FUS gene. This initiative is described as one of the first known documented attempts to prevent ALS onset in a human.
Promising Outcomes and Renewed Hope
While Vierstra's sisters developed complications and died, Vierstra reported that the treatment extended their lives. Following one year of treatment, the mild abnormalities detected in Vierstra's muscle testing normalized. Vierstra has not developed ALS and has outlived many family members affected by the disease. He continues his work as a scientist and engages in activities such as skiing, hiking, and global travel, reporting a renewed sense of future possibilities.
Future Implications for ALS Treatment
Dr. Shneider has stated that this research holds significant promise. He expressed hope that it could potentially transform ALS into a manageable, non-fatal disease. Insights gained from familial ALS research are hoped to benefit individuals with non-familial forms of the disease.
The Eleanor and Lou Gehrig ALS Center at Columbia University is working to expand its research beyond FUS-ALS. This includes developing individualized gene-based therapies for other rare genetic forms of ALS, under initiatives such as "Silence ALS."
Dr. Shneider has stated that this research holds significant promise, expressing hope that it could potentially transform ALS into a manageable, non-fatal disease.